MRI, PCA3, OR PHI TO PREDICT PROSTATE CANCER AFTER AN INITIAL NEGATIVE BIOPSY? RESULTS OF A PROSPECTIVE STUDY

被引：1
|
作者：
Porpiglia, Francesco
Russo, Filippo
Manfredi, Matteo
Mele, Fabrizio
Poggio, Massimiliano
Grande, Susanna
Fiori, Cristian
Bollito, Enrico
Papotti, Mauro
Molineris, Ivan
Regge, Daniele
机构：
来源：
JOURNAL OF UROLOGY | 2014年 / 191卷 / 04期
关键词：
D O I：
10.1016/j.juro.2014.02.2232
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP69-13
引用
收藏
页码：E819 / E820
页数：2
相关论文
共 50 条
  • [1] A COMPARISON BETWEEN MULTIPARAMETRIC MRI, PCA3, AND PHI IN THE PREDICTION OF PROSTATE CANCER AFTER AN INITIAL NEGATIVE BIOPSY
    Porpiglia, Francesco
    Russo, Filippo
    Manfredi, Matteo
    Mele, Fabrizio
    Grande, Susanna
    Fiori, Cristian
    Cattaneo, Giovanni
    Garrou, Diletta
    Amparore, Daniele
    Bollito, Enrico
    Papotti, Mauro
    Regge, Daniele
    [J]. ANTICANCER RESEARCH, 2014, 34 (05) : 2670 - 2670
  • [2] Predicting prostate biopsy results—PCA3 versus phi
    Stacy Loeb
    [J]. Nature Reviews Urology, 2015, 12 : 130 - 131
  • [3] CAN PROSTATE CANCER GENE 3 (PCA3) PREDICT INITIAL BIOPSY OUTCOME?
    de la Taille, Alexandre
    Irani, Jacques
    de Reijke, Theo M.
    Haese, Alexander
    [J]. JOURNAL OF UROLOGY, 2009, 181 (04): : 655 - 655
  • [4] Additional value of PCA3 density to predict initial prostate biopsy outcome
    Ruffion, A.
    Perrin, P.
    Devonec, M.
    Champetier, D.
    Decaussin, M.
    Paparel, P.
    Vlaeminck-Guillem, V.
    [J]. WORLD JOURNAL OF UROLOGY, 2014, 32 (04) : 917 - 923
  • [5] Additional value of PCA3 density to predict initial prostate biopsy outcome
    A. Ruffion
    P. Perrin
    M. Devonec
    D. Champetier
    M. Decaussin
    P. Paparel
    V. Vlaeminck-Guillem
    [J]. World Journal of Urology, 2014, 32 : 917 - 923
  • [6] Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients
    Goode, Roland R.
    Marshall, Susan J.
    Duff, Michael
    Chevli, Eric
    Chevli, K. Kent
    [J]. PROSTATE, 2013, 73 (01): : 48 - 53
  • [7] Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy
    Jose Rubio-Briones
    Angel Borque
    Luis M. Esteban
    Juan Casanova
    Antonio Fernandez-Serra
    Luis Rubio
    Irene Casanova-Salas
    Gerardo Sanz
    Jose Domínguez-Escrig
    Argimiro Collado
    Alvaro Gómez-Ferrer
    Inmaculada Iborra
    Miguel Ramírez-Backhaus
    Francisco Martínez
    Ana Calatrava
    Jose A. Lopez-Guerrero
    [J]. BMC Cancer, 15
  • [8] Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy
    Rubio-Briones, Jose
    Borque, Angel
    Esteban, Luis M.
    Casanova, Juan
    Fernandez-Serra, Antonio
    Rubio, Luis
    Casanova-Salas, Irene
    Sanz, Gerardo
    Dominguez-Escrig, Jose
    Collado, Argimiro
    Gomez-Ferrer, Alvaro
    Iborra, Inmaculada
    Ramirez-Backhaus, Miguel
    Martinez, Francisco
    Calatrava, Ana
    Lopez-Guerrero, Jose A.
    [J]. BMC CANCER, 2015, 15
  • [9] PSA, PCA3 and the phi losophy of prostate cancer management
    Melichar, Bohuslav
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (04) : 707 - 712
  • [10] Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer?
    Remzi, Mesut
    Haese, Alexander
    van Poppel, Hein
    de la Taille, Alexandre
    Stenzl, Arnulf
    Hennenlotter, Joerg
    Marberger, Michael
    [J]. BJU INTERNATIONAL, 2010, 106 (08) : 1138 - 1142
12345